Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 1;2(4):85155.
doi: 10.56305/001c.85155. eCollection 2023.

When Apixaban and Rivaroxaban Interfere With Anti-Xa Assays: A Cohort Study

Georges El Hasbani  1 , Mahmoud Abdelrahman  1 , Mark Baker  2 , Christopher Janowiecki  1
Affiliations

When Apixaban and Rivaroxaban Interfere With Anti-Xa Assays: A Cohort Study

Georges El Hasbani et al. J Brown Hosp Med. .

Abstract

Background: The use of direct factor Xa inhibitors, such as apixaban and rivaroxaban, has improved medication adherence. However, in certain situations during hospital admission, patients on these medications may need to be transitioned to unfractionated heparin (UFH) infusions. This transition can skew results of anticoagulation monitoring, such as the anti-Xa assay, due to residual factor-Xa inhibitor activity.

Methods: We conducted this retrospective chart among admitted patients to St. Vincent's Medical Center in Bridgeport, CT between December 2020 till June 2022. Patients who were maintained on Apixaban or Rivaroxaban, factor-Xa inhibitors, and were transitioned to unfractionated intravenous drip were included. A baseline plasma anti-Xa level was noted. Assessment for thrombotic or bleeding events during hospitalization was performed.

Results: A total of 48 patients were included in this study. The majority of patients were bridged to UFH for NSTEMI (31%) or pre-procedure (23%). The mean baseline anti-Xa for all patients was 0.92 U/mL. Twelve patients (25%) and one patient (2%) of patients had bleeding and thrombotic events, respectively. Although the mean baseline anti-Xa level was higher for patients who had an adverse event compared to no event, the difference was non-statistically significant. Fifty seven percent of patients who had an adverse event had a supratherapeutic plasma anti-Xa baseline level. A gastrointestinal bleed was the most common type of bleeding event.

Conclusions: To prevent thrombotic or bleeding events, we suggest adopting a standard practice of obtaining a baseline anti-Xa level in patients with recent exposure to factor Xa inhibitors in order to guide the timing of UFH initiation, the dosing of heparin, and determine the need for alternative assays, such as the activated partial thromboplastin clotting time.

Keywords: Anticoagulation; Side effects; antiXa; apixaban; coagulation assays.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.. The indications to transition from direct factor Xa inhibitors intravenous UFH during hospitalization.
NSTEMI: Non-ST elevation myocardial infarction; MVD: Multi-vessel disease; A fib: Atrial fibrillation; VTE: Venous thromboembolic event; Pre-op: Pre-operation
See this image and copyright information in PMC

References

    1. Longitudinal medication reconciliation at hospital admission, discharge and post-discharge. Daliri Sara, Bouhnouf Mounia, van de Meerendonk Henk W.P.C., Buurman Bianca M., Scholte op Reimer Wilma J.M., Kooij Marcel J., Karapinar – Çarkit Fatma. Apr;2021 Research in Social and Administrative Pharmacy. 17(4):677–684. doi: 10.1016/j.sapharm.2020.05.022. https://doi.org/10.1016/j.sapharm.2020.05.022 - DOI - DOI - PubMed
    1. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. Comerota Anthony J., Ramacciotti Eduardo. Jul;2016 The American Journal of the Medical Sciences. 352(1):92–106. doi: 10.1016/j.amjms.2016.03.018. https://doi.org/10.1016/j.amjms.2016.03.018 - DOI - DOI - PubMed
    1. Gilchrist Ian C. Catheterization and Cardiovascular Interventions. 2. Vol. 93. Wiley; Heparin, bivalirudin, or the best of both for STEMI interventions; pp. 248–249.https://doi.org/10.1002/ccd.28091 - DOI - DOI - PubMed
    1. Unfractionated heparin or low-molecular-weight heparin in the elderly. Dorobantu Maria, Bogdan Stefan. Nov;2016 International Journal of Cardiology. 222:1084–1090. doi: 10.1016/j.ijcard.2016.07.208. https://doi.org/10.1016/j.ijcard.2016.07.208 - DOI - DOI - PubMed
    1. Anti-Xa assays: What is their role today in antithrombotic therapy? Centeno E.H., Militello M., Gomes M.P. 201986:417–25. - PubMed

LinkOut - more resources